175 related articles for article (PubMed ID: 23919512)
1. Identification of novel key amino acids at the interface of the transmembrane domains of human BST-2 and HIV-1 Vpu.
Pang X; Hu S; Li J; Xu F; Mei S; Zhou J; Cen S; Jin Q; Guo F
Retrovirology; 2013 Aug; 10():84. PubMed ID: 23919512
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the interface of the bone marrow stromal cell antigen 2-Vpu protein complex via computational chemistry.
Zhou J; Zhang Z; Mi Z; Wang X; Zhang Q; Li X; Liang C; Cen S
Biochemistry; 2012 Feb; 51(6):1288-96. PubMed ID: 22264038
[TBL] [Abstract][Full Text] [Related]
3. Identification of amino acids in the human tetherin transmembrane domain responsible for HIV-1 Vpu interaction and susceptibility.
Kobayashi T; Ode H; Yoshida T; Sato K; Gee P; Yamamoto SP; Ebina H; Strebel K; Sato H; Koyanagi Y
J Virol; 2011 Jan; 85(2):932-45. PubMed ID: 21068238
[TBL] [Abstract][Full Text] [Related]
4. Functional antagonism of rhesus macaque and chimpanzee BST-2 by HIV-1 Vpu is mediated by cytoplasmic domain interactions.
Yoshida T; Koyanagi Y; Strebel K
J Virol; 2013 Dec; 87(24):13825-36. PubMed ID: 24109238
[TBL] [Abstract][Full Text] [Related]
5. [Establishment of a high-throughput screening assay for interaction inhibitor between BST-2 and Vpu].
Pang XJ; Hu SQ; Zhang Y; Cen S; Jin Q; Guo F
Bing Du Xue Bao; 2012 Nov; 28(6):633-8. PubMed ID: 23367562
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes.
Iwabu Y; Fujita H; Kinomoto M; Kaneko K; Ishizaka Y; Tanaka Y; Sata T; Tokunaga K
J Biol Chem; 2009 Dec; 284(50):35060-72. PubMed ID: 19837671
[TBL] [Abstract][Full Text] [Related]
7. The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu.
Rong L; Zhang J; Lu J; Pan Q; Lorgeoux RP; Aloysius C; Guo F; Liu SL; Wainberg MA; Liang C
J Virol; 2009 Aug; 83(15):7536-46. PubMed ID: 19474106
[TBL] [Abstract][Full Text] [Related]
8. The C-Terminal End of HIV-1 Vpu Has a Clade-Specific Determinant That Antagonizes BST-2 and Facilitates Virion Release.
Sharma S; Jafari M; Bangar A; William K; Guatelli J; Lewinski MK
J Virol; 2019 Jun; 93(11):. PubMed ID: 30867310
[TBL] [Abstract][Full Text] [Related]
9. Vpu of a Simian Immunodeficiency Virus Isolated from Greater Spot-Nosed Monkey Antagonizes Human BST-2 via Two AxxxxxxxW Motifs.
Yao W; Yoshida T; Hashimoto S; Takeuchi H; Strebel K; Yamaoka S
J Virol; 2020 Jan; 94(2):. PubMed ID: 31666374
[TBL] [Abstract][Full Text] [Related]
10. Polarity changes in the transmembrane domain core of HIV-1 Vpu inhibits its anti-tetherin activity.
Lv M; Wang J; Wang X; Zuo T; Zhu Y; Kong W; Yu X
PLoS One; 2011; 6(6):e20890. PubMed ID: 21674066
[TBL] [Abstract][Full Text] [Related]
11. βTrCP is Required for HIV-1 Vpu Modulation of CD4, GaLV Env, and BST-2/Tetherin.
Song YE; Cyburt D; Lucas TM; Gregory DA; Lyddon TD; Johnson MC
Viruses; 2018 Oct; 10(10):. PubMed ID: 30347660
[TBL] [Abstract][Full Text] [Related]
12. Ubiquitination of BST-2 protein by HIV-1 Vpu protein does not require lysine, serine, or threonine residues within the BST-2 cytoplasmic domain.
Gustin JK; Douglas JL; Bai Y; Moses AV
J Biol Chem; 2012 Apr; 287(18):14837-50. PubMed ID: 22383521
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 Vpu antagonizes BST-2 by interfering mainly with the trafficking of newly synthesized BST-2 to the cell surface.
Dubé M; Paquay C; Roy BB; Bego MG; Mercier J; Cohen EA
Traffic; 2011 Dec; 12(12):1714-29. PubMed ID: 21902775
[TBL] [Abstract][Full Text] [Related]
14. Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein.
Vigan R; Neil SJ
J Virol; 2010 Dec; 84(24):12958-70. PubMed ID: 20926557
[TBL] [Abstract][Full Text] [Related]
15. A novel peptide to disrupt the interaction of BST-2 and Vpu.
Mi Z; Wang X; He Y; Li X; Ding J; Liu H; Zhou J; Cen S
Biopolymers; 2014 May; 102(3):280-7. PubMed ID: 24676648
[TBL] [Abstract][Full Text] [Related]
16. Sites of action of HIV-1 Vpu in BST-2/tetherin downregulation.
Arias JF; Iwabu Y; Tokunaga K
Curr HIV Res; 2012 Jun; 10(4):283-91. PubMed ID: 22524176
[TBL] [Abstract][Full Text] [Related]
17. High-Throughput NanoBiT-Based Screening for Inhibitors of HIV-1 Vpu and Host BST-2 Protein Interaction.
Li B; Dong X; Zhang W; Chen T; Yu B; Zhao W; Yang Y; Wang X; Hu Q; Wang X
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502213
[TBL] [Abstract][Full Text] [Related]
18. Simian Immunodeficiency Virus SIVgsn-99CM71 Vpu Employs Different Amino Acids To Antagonize Human and Greater Spot-Nosed Monkey BST-2.
Yao W; Strebel K; Yamaoka S; Yoshida T
J Virol; 2022 Feb; 96(4):e0152721. PubMed ID: 34878886
[TBL] [Abstract][Full Text] [Related]
19. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism.
Douglas JL; Viswanathan K; McCarroll MN; Gustin JK; Früh K; Moses AV
J Virol; 2009 Aug; 83(16):7931-47. PubMed ID: 19515779
[TBL] [Abstract][Full Text] [Related]
20. A comparative mutational analysis of HIV-1 Vpu subtypes B and C for the identification of determinants required to counteract BST-2/Tetherin and enhance viral egress.
Douglas JL; Bai Y; Gustin JK; Moses AV
Virology; 2013 Jul; 441(2):182-96. PubMed ID: 23582304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
